UroGen Pharma

Company Overview

Snapshot

Founded in April 2004 by Asher Holtzer, UroGen Pharma operates with 201–500 employees. The company has raised a total of $522.2 million across 11 funding rounds from 8 investors. In October 2024, the FDA accepted UroGen's New Drug Application for UGN-102, a potential non-surgical treatment for bladder cancer.

Business overview

UroGen Pharma is a biotech company specializing in novel solutions for urologic oncology and diseases. The company's core technology is RTGel, a proprietary sustained-release, hydrogel-based platform designed to enhance the therapeutic profiles of existing drugs by enabling longer exposure of the urinary tract tissue to medications. UroGen's lead product candidates, UGN-101 (MitoGel) and UGN-102 (VesiGel), aim to non-surgically remove tumors and treat various forms of non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals and Drug Delivery.

Strategic signal

UroGen Pharma is advancing its pipeline with a new U.S. patent allowance for next-generation mitomycin-based products, expected to provide protection until December 2041, as announced in September 2024. This patent signals a strong commitment to intellectual property and long-term market exclusivity for its innovative drug delivery platform in urologic oncology, reinforcing investor confidence in the company's future revenue streams and competitive advantage.

Company Intelligence Q&A

What was a significant regulatory milestone for UroGen Pharma in October 2024?

In October 2024, the FDA accepted UroGen's New Drug Application for UGN-102, which is being developed as a potential non-surgical treatment for bladder cancer.

What was a key intellectual property development for UroGen Pharma in September 2024?

In September 2024, UroGen Pharma received a new U.S. patent allowance for its next-generation mitomycin-based products, which is expected to provide patent protection until December 2041.

When did UroGen Pharma begin subject dosing in a Phase III bladder cancer drug trial?

UroGen Pharma began subject dosing in a Phase III bladder cancer drug trial in October 2024.

What was the outcome of the ENVISION Trial for UGN-102, published in October 2024?

In October 2024, results from the ENVISION Trial were published in the Journal of Urology, reporting an 82.3% duration of response 12 months after achieving complete response for UGN-102, positioning it as a potentially first FDA-approved non-surgical treatment for LG-IR-NMIBC.

What was the status of UGN-103 development in October 2024?

In October 2024, the first patient was dosed in a Phase 3 clinical trial of UGN-103, a next-generation mitomycin-based formulation in development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.